Study Title | Phase 1 Evaluation Of Ly2606368& A Molecularly Targeted Chk1/2 Inhibitor Therapy& In Combination With Cyclophosphamide Or Gemcitabine For Children And Adolescents With Refractory Or Recurrent Group 3/Group 4 Or Shh Medulloblastoma Brain Tumors |
---|---|
Protocol ID | SJ ELiOT |
Disease (Sub Disease) | Brain and Spinal Tumours (Medulloblastoma/ PNET) |
Diagnosis Stage | Relapse/ refractory |
Sponsor | Australian and New Zealand Children's Haematology Oncology Group/ St. Jude Children's Research Hospital |
Collaborators | Eli Lilly and Company |
Links | https://clinicaltrials.gov/ct2/show/NCT04023669 |
Trial Status | Closed to Recruitment |
Trial Open Date | 02/10/2019 |
Study Type | Treatment |
Phase | Phase 1 |
Age Eligibility | 1 year to 25 years |
International registry ID's | NCT04023669 |